Provider review
Invyncible review
Adding ingredients lowers the price here, and every product is permanently struck through.
The catalog card shows a bare figure, but the product page behind it names the dose and re-prices as you move up — so the advertised number is the lowest-dose basis, not a flat rate.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
Invyncible
$149–$402.50, quoted off the lowest dose
- Vs median
- Not comparable — no per-month rate is published — the verified string carries no monthly figure
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Quotes off the lowest dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
Two features of this catalog are worth your time. The first is that the price does not move the way the ingredients do. A semaglutide program with glycine and vitamin B12 added costs less than plain semaglutide, and the same holds for tirzepatide — but tirzepatide with B12 and no glycine costs more than either. Whatever is driving those numbers, it is not the cost of what is in the vial, which means you cannot reason about value from the formulation list and should treat the tiers as separate products rather than as a ladder. The second is the discounting, which is universal and therefore uninformative. Every item on the page is struck through from a higher figure, and the size of the gap swings from a tenth to well over half depending on the product. A discount that applies to everything permanently is a price, not a saving, and the higher number is a rhetorical device rather than something anyone was charged. What the catalog card hides, the product page states: each program names the dose it buys in milligrams, and the figure climbs with it — across three vial sizes for plain semaglutide and five programs for tirzepatide — while the site's own FAQ confirms outright that cost can rise when the dose increases. So the number you meet first is the lowest-dose basis, not a rate that holds as you titrate. Supply length is the part that is still inconsistent. Tirzepatide programs each carry a four-week label in the title and plain semaglutide publishes a four-to-five-week dosing example, but the glycine and B12 programs name a dose and no period at all, so those figures cannot be turned into a monthly rate from the page.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want several formulations priced separately rather than bundled into one plan
- You want either molecule available plain or combined, each with its own figure
- You want the dose behind the price named, and the next step up priced before you commit
Look elsewhere if
- You want a figure that holds as you titrate. This one is quoted off the lowest dose and climbs
- You are measuring the advertised saving. Every product is permanently discounted
- You expect the price to track the formulation. Here it does not
What it actually costs
Price as published
The catalog card prints a bare figure, but each product page names the dose behind it and re-prices as the program changes: plain semaglutide is $192.50 at the 2.5 mg vial, $262.50 at 5 mg and $350 at 10 mg, and tirzepatide runs $210.00 to $402.50 across five programs. The cheapest lines are tirzepatide with glycine and B12 at $180.00 and semaglutide with glycine and B12 at $149.00; tirzepatide with B12 is $260.00. Invyncible's own FAQ says outright that cost can go up when the dose increases, so the advertised number is the lowest-dose basis · ★ the pricing is still not monotonic in ingredients: adding glycine and B12 makes both molecules CHEAPER than their plain versions, while adding B12 alone to tirzepatide makes it dearer than either · every product carries a struck-through comparison price and the discounts are wildly inconsistent — a 57% gap on one formulation, 10% on another — which makes the struck figures rhetorical rather than a rate to measure a saving against · the current and struck figures are printed with the CURRENT one first, the opposite order from other catalogs here; this was resolved by reading the price elements themselves rather than the text order · supply length is published unevenly: the tirzepatide programs are each titled "(4 weeks)" and plain semaglutide publishes a four-to-five-week dosing example, while the glycine and B12 programs name a dose and no period at all, and a sibling product names its duration in its own title, "Tirzepatide/B3 Program (2-months)" · providers are described as licensed with no long-term commitment, refills are requested rather than auto-billed, and the card is only charged if a provider approves
- Vs median
- Not comparable — no per-month rate is published — the verified string carries no monthly figure
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Quotes off the lowest dose
States plainly that its advertised figures are based on the lowest dosage and that higher doses may cost more. On a general ranking that is a warning; for someone staying small it is the one model that bills accordingly.
36 of the 373 programs we track price a small dose this way. Every figure is readable before intake on the open catalog, and each product page re-prices as the dose program changes — which is what makes the basis legible: the plain programs step up across three vial sizes for semaglutide and five for tirzepatide, and the site's own FAQ confirms outright that cost can rise when the dose increases. So the advertised number is the lowest-dose basis rather than a flat rate. ★ The price still does not track the formulation: adding glycine and B12 makes both molecules CHEAPER than plain, so the tiers are separate products rather than a ladder. An oral semaglutide capsule program is priced separately. The period is published for tirzepatide, whose programs each carry a four-week label in the title, and given as a four-to-five-week dosing example for plain semaglutide; the glycine and B12 programs name their doses but no supply length. No low-dose product is sold as its own SKU.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- Several formulations are priced separately rather than bundled into one plan.
- Both molecules are available plain or combined, each with its own figure.
- Every dose program names the milligrams it buys, and the next step up is priced before you commit.
- No long-term commitment is required, refills are requested rather than auto-billed, and the card is only charged if a provider approves.
Pharmacy, labs and oversight
Invyncible does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
2 of 4 published openly
What Invyncible publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Not published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
Two features of this catalog are worth a reader's time. The first is that the price does not move the way the ingredients do. A semaglutide program with glycine and vitamin B12 added costs less than plain semaglutide, and the same holds for tirzepatide — but tirzepatide with B12 and no glycine costs more than either. Whatever is driving those numbers, it is not the cost of what is in the vial, which means a reader cannot reason about value from the formulation list and should treat the tiers as products rather than as a ladder. The second is the discounting, which is universal and therefore uninformative. Every item on the page is struck through from a higher figure, and the size of the gap swings from a tenth to well over half depending on the product. A discount that applies to everything permanently is a price, not a saving, and the higher number is a rhetorical device rather than something a reader was ever charged. What the catalog card leaves out, the product page supplies: each program names the dose it buys in milligrams, and the figure climbs with it, which the site's own FAQ confirms. So the number a reader meets first is the lowest-dose basis rather than a rate that holds through titration. Supply length is the part that is still uneven — the tirzepatide programs carry a four-week label and plain semaglutide publishes a four-to-five-week dosing example, but the glycine and B12 programs give a dose and no period, so those figures cannot be turned into a monthly rate from the page.
The honest cons
The figure is quoted off the lowest dose and climbs as you titrate.
- Every product is permanently struck through, at wildly inconsistent ratios.
- The price does not track the formulation, so the tiers cannot be reasoned about.
- The glycine and B12 programs state no supply length, so those figures cannot be compared as monthly rates.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
Invyncible is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#254 of 373
Ordered with the companies that pay us first, and Invyncible is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
Elara MD
$249/mo at 0.2 mg/wk semaglutide
- Vs median
- $80/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Quotes off the lowest dose
- Dispensed
- Compounded, 503A pharmacy
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the Elara MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.